【GBM】《Lantern Pharma》旗下「膠質母細胞瘤」藥物「LP-184」獲FDA快速批准

 【GBM】《Lantern Pharma: LTRN》旗下「膠質母細胞瘤」藥物「LP-184」獲FDA快速批准

 文章出處  

Businesswire 

 

 原文標題  

Lantern Pharma’s Investigational Drug-Candidate, LP-184, Receives Fast-Track Designation in Glioblastoma from the FDA 

 

 Twitter  

https://x.com/aimedadviser/status/1846695479079497774 

 

 文章序號  

6473 

 

智醫科學－AI醫療技術、應用與市場動態

Copyright ©2024 智醫科學 MEDai.tw All rights reserved.

The content of this site is intended for healthcare and medical professionals.